NCT02943681

A Second Dose of Measles Vaccine (MV) in the Second Year of Life

Boosting the Beneficial Non-specific Effects of Live Attenuated Vaccines: A Randomized Controlled Trial (RCT) of a Second Dose of Measles Vaccine (MV) in the Second Year of Life

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 3,812 (actual)
• Sponsor: Bandim Health Project · Academic / Other
• Sex: All
• Age: 18 Months – 24 Months
• Healthy volunteers: Accepted

Summary

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

Conditions

• Child Mortality
• Child Morbidity

Interventions

Type	Name	Description
BIOLOGICAL	Measles vaccine

Timeline

• Start date: 2016-10-01
• Primary completion: 2020-05-01
• Completion: 2021-05-01
• First posted: 2016-10-25
• Last updated: 2024-01-19

Locations

1 site across 1 country: Guinea-Bissau